Personalized Therapy Design for MPN Using Predictive Simulation Methodology with In Vitro, Ex Vivo, and In Vivo Validation

Background: Currently approved therapies for myeloproliferative neoplasms (MPNs) are limited to cytoreductive agents such as hydroxyurea and the Jak1/2 inhibitor ruxolitinib.

Blood Journal 2014